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Statement of translational relevance: Radiomics, the automated high-throughput 
extraction of multidimensional imaging features captures microscale information hidden 
within conventional imaging beyond what is visible to the naked human eye. The linkage of 
imaging phenotypes with genomic data is termed radiogenomics. Fundamental to 
radiogenomics is the hypothesis that expression of specific sets of genes or driver mutations 
impact the extractable imaging features, but this has not been directly demonstrated in a 
highly robust model; to date, the linkages between imaging and genomics remain at a 
correlative stage and lack established causality. In this study, we seek to address this gap in 
knowledge; we bring forward an approach for integrated end-to-end methodology for 
extraction of imaging radiomic features and validation in both a preclinical closed model 
system and patient cohort. Further, we demonstrate the potential of radiomics in co-clinical 
trials. To our knowledge, this is the first study functionally validating imaging-molecular 
features.
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ABSTRACT 
 
PURPOSE: Radiomics is the extraction of multidimensional imaging-features which when 
correlated with genomics is termed radiogenomics. However, radiogenomic biological 
validation is not sufficiently described in the literature. We seek to establish causality 
between differential gene expression status and MRI-extracted radiomic-features in 
glioblastoma.  
 
METHODS: Radiogenomic predictions and validation were done using the Cancer 
Genome Atlas and Repository of Molecular Brain Neoplasia Data glioblastoma patients 
(N=93) and orthotopic xenografts (OX)(N=40). Tumor phenotypes were segmented, and 
radiomic-features extracted using the developed radiome-sequencing pipeline. Patients and 
animals were dichotomized based on Periostin (POSTN) expression levels. RNA and protein 
levels confirmed RNAi-mediated POSTN knockdown in OX. Total RNA of tumor cells 
isolated from mouse brains (knockdown and control) was used for microarray-based 
expression profiling. Radiomic-features were utilized to predict POSTN expression status in 
patient, mouse, and inter-species. 
 
RESULTS: Our robust pipeline consists of segmentation, radiomic-feature extraction, 
feature normalization/selection, and predictive-modeling. The combination of skull 
stripping, brain-tissue focused normalization and patient-specific normalization are unique to 
this study, providing comparable cross-platform, cross-institution radiomic-features. POSTN 
expression status was not associated with qualitative or volumetric MRI parameters. 
Radiomic-features significantly predicted POSTN expression status in patients (AUC 
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76.56%, sensitivity/specificity: 73.91/78.26%) and OX (AUC 92.26%, 
sensitivity/specificity: 92.86%/91.67%). Furthermore, radiomic-features in OX were 
significantly associated with patients with similar POSTN expression levels (AUC 93.36%, 
sensitivity/specificity: 82.61%/95.74%; p-value 02.021E-15). 
 
CONCLUSION: We determined causality between radiomic texture features and POSTN 
expression levels in a pre-clinical model with clinical validation. Our biologically validated 
radiomic pipeline also showed the potential application for human-mouse matched co-
clinical trials.  
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INTRODUCTION 
 
Imaging has transformed the medical field by providing a non-invasive method to interrogate 
the human body and underlying biological processes. Particularly in cancer patients, imaging plays a 
key role throughout the entire treatment paradigm ranging from diagnosis and assessing treatment 
response to post-care follow-up. However, despite recent exponential refinements in imaging 
technologies in terms of acquisition time and resolution, we have barely begun to tap the potential of 
imaging to characterize tissues or tumors beyond qualitative description or gross tumor size on 
routine imaging sequences. In fact, all current imaging assessment criteria (such as response 
evaluation criteria in solid tumors (RECIST), response assessment in neuro-oncology (RANO), 
immune related RECIST (irRECIST), and immune related response criteria (irRC)) used to evaluate 
tumor response in the clinical setting and in clinical trials are dependent on changes in tumor size 
and do not accurately capture responses to therapy [1-4]. With the development of immune and 
molecularly targeted therapies, alternative imaging assessment criteria and markers are needed that 
go beyond mere changes in tumor size. In fact, with some therapies such as immunotherapy, 
positive response to treatment is associated with initial decrease in tumor size in only 10% of 
patients, while other positive-responders fail to show such a measurable initial decline in tumor size 
[4]. This uncoupling of tumor metrics and response to therapy is a clinical dilemma and challenge 
for clinicians. Further, the specific “makeup” of a tumor’s imaging characteristics reflects 
underlying molecular processes, which cannot be evaluated using changes in tumor size alone. 
Unlocking the full breadth of data contained in routine imaging studies would enable the 
identification of high quality, noninvasive, clinically relevant, and actionable imaging markers.  
Radiomics, an emerging field within imaging, is poised to do just that. An automated high-
throughput extraction of multidimensional imaging features (on a pixel and voxel level), radiomics 
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captures microscale information hidden within conventional imaging and beyond what is visible to 
the naked human eye [5-7]. Like the layer of complexity and resolution that genomics has added to 
tumor biology, radiomics similarly adds to conventional imaging. However, a critical need exists to 
understand the biological underpinnings of imaging, specifically radiomics, for informed clinical 
decision making. This also necessitates a proper understanding of how changes in genomics affect 
imaging information. With radiomics, it is now realistic to begin testing precise linkages and 
investigate causality between imaging and genomics. Understanding the molecular bedrocks of 
radiomics is important due to imaging’s inherent advantages; in contrast to genomic analyses which 
are often performed on only a fraction of the tumor, an advantage of imaging is that it assesses the 
entire three-dimensional tumor volume inclusive of spatial heterogeneity [8, 9]. Recent studies have 
demonstrated an association between imaging features (also termed phenotypes) and cancer 
histology, tumor grades, and genomics [5, 10-13]. The linkage of imaging phenotypes with genomic 
data is termed radiogenomics (also termed imaging genomics)[10]. Fundamental to radiogenomics 
is the hypothesis that expression of specific sets of genes or driver mutations impact the extractable 
imaging features, but this has not been directly demonstrated in a highly robust model.   
 Imaging-molecular connections must be established in a robust manner, specifically by 
establishing causality (as opposed to correlations), for its acceptance as a validated tool. To establish 
causality, a closed system is required for in-vivo manipulation of genomic expression patterns and 
linkage to radiomic features using a preclinical model system. A few studies have tried to elucidate 
the biological significance of imaging characteristics [14, 15]. Joo et al. demonstrated that xenograft 
tumors produced from patient-derived glioblastoma (GBM) cell lines were similar to their paired 
human parental tumors [14]. In the latter study, they found the invasiveness of the parental tumor on 
MRI correlated with invasive measures based on paraffin histopathology sections of the xenograft 
tumor. In a different study using a heterotopic colorectal cancer mouse model, Panth et al. found 
Research. 
on July 30, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3420 
 7
changes in computerized tomography (CT) imaging features after induced alterations in gene 
expression and radiation treatment [15]. However, to date, the linkages between imaging and 
genomics largely remain at a correlative stage and lack established causality in a model system 
relevant for human disease.  
 In this study, we seek to address this gap in knowledge which can be expected to change patient 
management. To our knowledge, this is the first study to establish causality between imaging-
molecular (radiogenomic) features. In this study, we bring forward an approach for an integrated 
end-to-end methodology for extraction of imaging radiomic features and its validation in both a 
preclinical closed model system and in a clinical patient cohort. We use the most common primary 
malignant brain tumor characterized by extreme heterogeneity and poor patient survival [16-18], 
GBM, as the solid cancer prototype in this study. Periostin (POSTN), was used as the gene 
prototype, given its previous radiogenomic description in the first published quantitative 
radiogenomic study in glioma of the Cancer Genome Atlas (TCGA)[13]; its more recent surfacing 
as an important gene involved in GBM invasion[19], one of  the most important causes of GBM 
recurrence; and its potential use as a GBM therapeutic target in developing clinical trials[20]. 
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METHODS 
Patient-derived imaging, clinical and genomic material were collected from TCGA, 
The Cancer Imaging Archive (TCIA) and the Repository of Molecular Brain Neoplasia Data 
(REMBRANDT); all patient data collection were HIPAA compliant and approved by 
MDACC’s Institutional Review Board (PA130720).  Analyses were based on a total of 79 
TCGA patients and 14 REMBRANDT patients for whom complete baseline MRI data and 
POSTN gene expression data were available. Detailed demographic information is presented 
in Table 1a and b. 
For the preclinical portion of the study, MD Anderson Cancer Center (MDACC) 
patient–derived glioma stem cells (GSC) lines were isolated in accordance with a protocol 
(LAB04-0001) approved by MDACC’s Institutional Review Board. Patient consent was 
obtained. For the cell study, the IRB issued a waiver of informed consent since data 
collection was retrospective. All animal experiments complied with institutional regulations 
and was approved by MDACC’s Institutional Animal Care and Use Committee (protocol 
00001100) in accordance with the guidelines of the American Association for Laboratory 
Animal Science.  
 
Image segmentation 
Image analysis and software 
We used 3D Slicer version 4.3.1 (www.slicer.org), an open-source image analytics 
platform, for tumor segmentation [21-23]. The segmented images were reviewed in 
consensus by two board-certified neuroradiologists with 9 (R.R.C.) and 35 (A.J.K.) years of 
experience. For the segmentation of the mouse MRI, we followed an approach similar to that 
used for the patient imaging analysis using 3D Slicer software. In brief, conventional MRI 
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series were co-registered to bring all mouse images to same space, using a registration 
method identical to the method used in humans (detailed below). Then, we outlined 
different tumor phenotypes including edema, enhancement and necrosis on the 
corresponding imaging series similar to the approach used in humans (detailed below). The 
image analysis team was blinded to the patient cohort as well as animal groups (control vs. 
knockdown). 
 
Volume selection 
We used contrast-enhanced axial T1-weighted imaging (T1WI) sequences and pre-
contrast axial Fluid-Attenuated Inversion Recovery (FLAIR) sequences. Contrast-enhanced 
T1WI was used for segmentation of the enhancing component (i.e., active enhancing tumor) 
and non-enhancing central tumor component (i.e., necrosis). The edema/invasion portion 
was segmented using the FLAIR sequence; this region was assessed based on the 
peritumoral hyperintensity seen on the FLAIR sequence (Fig. 1a). Hyperintensity on pre- 
contrast T1WI was used to assess hemorrhage. Of the 93 TCGA/TCIA/REMBRANDT 
patients, 1 was scanned with a 1T system (1.08%), 57 were scanned with a 1.5T system 
(61.3%), and 26 were scanned with a 3T system (28%). Scanner strength information was 
not available for 9 patients (9.7%).  Standard imaging parameters (slice thickness, voxel size, 
and slice gap) were used for each sequence (Supplementary Tables 1a, 1b). 
 
Image registration, segmentation, and model making 
Image registration and segmentation were done as previously published by our 
group[24]. Prior to image segmentation, within-patient image registration was performed to 
align the FLAIR imaging and contrast-enhanced T1WI into the same geometric space. 
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Images were registered using the General Registrations (BRAINS) Toolbox in 3D Slicer 
(affine registration, 12 degrees of freedom; Interpolation mode: Nearest Neighbor; 
https://www.slicer.org/wiki/Documentation/4.8/Registration/RegistrationLibrary), and the 
transformation matrix that maps each point of the reference image to the target’s image 
space was obtained. An adequate registration was designated as having an error of 2mm or 
less; all patient data were reviewed post-registration and if the error was more than 2mm 
then the patient was not included in the study. After image registration, images were 
segmented from the periphery (edema/invasion) to center (necrosis). Three distinct imaging 
phenotypes were segmented semi-automatically: edema/invasion, active enhancing tumor, 
and necrosis. A region of the contralateral normal-appearing white matter (opposite 
hemisphere and opposite lobe with respect to a line perpendicular to the midline) was also 
segmented for within-sequence normalization of the data. Hemorrhage appearing as 
hyperintensity on pre-contrast T1WI and contrast-enhancing vessels were subtracted from 
the FLAIR region to prevent contamination of the radiomic features obtained thereafter. The 
outlines of all segmented phenotypes were saved in a label volume. Finally, the inverted 
transformation matrix was applied to the label volume using nearest-neighbor interpolation 
to propagate the label volume to the original image. The volume of each phenotype was 
calculated by multiplying the number of voxels in a phenotype with the voxel volume. 
 
Radiome sequencing textural analysis 
Image preprocessing 
An overview of the approach used for radiomic feature extraction is shown in Fig. 
1b. All MRI scans were processed using the same pipeline. In the first step, we used 
FMRIB’s Brain Extraction Tool (BET) (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/BET) to remove 
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non-brain tissue from the anatomical MR images (Fig. 1b) [25, 26]. Contrast-enhanced 
T1WI was used as an input to BET. In all runs, the BET option for “bias field correction and 
neck removal” was selected. The resulting brain mask from BET was applied to the FLAIR 
sequences, thus removing non-brain tissue from those images also. In the second step, to 
account for scanner differences, we applied the Nyul intensity normalization algorithm to 
standardize the intensity scales across MR images of the same contrast (brain-specific 
normalization) (Fig. 1b) [27-29]. In brief, Nyul normalization involves the matching of the 
histograms between a reference image and the image of each subject in the cohort. In our 
implementation, firstly, the MR images (FLAIR and contrast-enhanced T1WI) of one 
patient from the cohort were randomly selected as the reference, and the corresponding 
histograms were obtained; the intensities of the tumor were excluded from the calculation of 
the histogram, because the tumor is an abnormal environment. In the next step, for each 
patient in the cohort, the histograms were mapped via a piecewise linear transformation to 
the reference histogram; thus, the resulting transformed image has similar range of 
intensities. Finally, we extracted radiomic textural features from each phenotype (i.e., 
edema/invasion, active enhancing tumor, and necrosis, and contralateral normal-appearing 
white matter) as well as the whole tumor volume on the FLAIR sequences and contrast-
enhanced T1WI. We followed an identical approach for processing the mouse MRI prior to 
radiomic feature calculation, except that we omitted the skull-stripping step. 
 
Textural radiome sequencing  
Whole radiome sequencing was performed, and the radiomic features were extracted 
for each phenotype and whole-tumor volume, using: a) intensity-level histogram (first-order 
features), and b) gray-level co-occurrence matrices (GLCMs; second-order features) [30]. 
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The intensity-level histogram is a function showing the number of voxels that have a 
specific intensity in the original volume of interest; thus, the extracted features provide 
information about the intensity distribution within the volume of interest. From each 
intensity-level histogram, the following 10 features were extracted: minimum, maximum, 
mean, standard deviation, skewness, kurtosis and four percentiles (1%, 5%, 95%, 99%) [31, 
32]. 
GLCM is a matrix computed from the original volume of interest, and each element 
of the matrix Ai,j represents the joint probability of two pixels with gray levels i and j with 
distance d apart and a certain angular direction θ. In our implementation, the GLCMs were 
calculated in four angular directions corresponding to in-plane rotations (θ=0°, 45°, 90°, 
135°) and d=1 voxel (Fig. 1b). Each GLCM is normalized to the sum of co-occurrence pairs; 
thus, the extracted features are independent of the number of original observations. From 
each GLCM, the following 20 texture features were extracted: autocorrelation, contrast, 
correlation, cluster shade, cluster prominence, dissimilarity, energy, entropy, homogeneity, 
maximum probability, variance, sum average, sum variance, sum entropy, difference 
variance, difference entropy, information measure of correlation 1 and 2, inverse difference 
moment, and normalized inverse difference moment [30, 33, 34]. To obtain invariant 
measures of the features across different rotations, we calculated the average, range, and 
angular variance of each feature for different θ, thereby resulting in 60 rotation-invariant 
texture features for each volume of interest for every gray level. 
In our implementation, the original images were discretized into N number of gray 
levels, where N=8, 16, 32, 64, or 256. Reducing the number of gray levels increases the 
signal-to-noise ratio and eliminates sparseness in the final GLCM. Intensity-level histogram-
based features were calculated using images discretized at 256 gray levels and GLCM-based 
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features were calculated using all gray levels. In summary, our analysis resulted in a total of 
310 radiomic features for each phenotype per MRI sequence. Taking into account the two 
MRI sequences (contrast-enhanced T1WI and T2/FLAIR) along with the phenotypes 
(edema/invasion, enhancing active tumor, and necrosis) and whole-tumor volume, a total of 
2,480 radiomic features (2,400 second-order and 80 first order features) were extracted from 
human GBM. An additional 620 radiomic features from the contralateral normal-appearing 
white matter were extracted from human MRIs and used for within- sequence normalization 
purposes. Similarly, in the case of mice, a total of 2,480 (2,400 second-order and 80 first 
order features) features were obtained. 
 
Extracted feature generation 
Out of the 310 radiomic features, a total of 300 MRI radiomic features per phenotype 
(enhancing active tumor, edema/invasion, necrosis, and whole GBM tumor) extracted per 
each imaging sequence (T1 and T2/FLAIR) were GLCM-based features as described above. 
This represents a total of 2,400 GLCM-based features extracted per tumor per patient (as 
well as per animal). To consider tumor volumes, 2,400 new variables (xij) were added by 
dividing each of these feature (f'ij ) by the corresponding phenotype volume. As a result, 
4,880 (volume-dependent and volume-independent) features (2,400 original second-order, 
2,400 volume-dependent second-order and 80 first order features) per tumor per patient 
(animal) were obtained. 
 
Contralateral normalization 
To account for differences in the image acquisition hardware and software used 
across TCGA institutions, we performed a patient-specific contralateral hemisphere 
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normalization of the features using the features extracted from the contralateral normal-
appearing white matter. Consequently, each feature (fij) was subtracted from the 
corresponding contralateral radiomic feature fij(wm). We assessed the performance of the 
patient-specific contralateral hemisphere normalization of the features across institutions, 
MRI scanner brands, and magnetic field strengths by plotting pre- and post- normalization 
feature distribution. 
 
Biostatistical radiomic analysis: feature selection, classification, and predictive 
modeling 
We used R software (version 3.4.0, R Foundation for Statistical Computing, Vienna, 
Austria) for all the statistical analysis: package xgboost (version 0.6.4.1) for the feature 
selection task and the Machine Learning package mlr (version 2.11) to build the binary 
logistic model of XGboost using “gbtree” booster for classification. Finally, Receiver 
Operating Characteristic (ROC) analysis was performed using pROC package (version 
1.9.1). AUC, sensitivity, specificity, PPV, NPV and p-values are reported for each LOOCV 
and prediction outputs. 
Radiomic feature selection 
Given the large number of features provided by radiomics, feature selection is the 
first step in the pipeline. For feature selection, we used Least Absolute Shrinkage and 
Selection Operator (LASSO) regularization (L1 regularization) technique[35]. LASSO is a 
regression analysis method that typically performs variable selection and regularization to 
enhance the prediction accuracy and avoid overfitting of the features on the model. L1 
regularization coupled with early stopping (at one third of the patient size) was used for 
feature selection to select the most important and relevant features required for the model 
Research. 
on July 30, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3420 
 15
building. Later, these important features were used for model building.  We used the latter 
models in the prediction of high versus low POSTN mice and human. The criteria of 
groupings into high versus low POSTN gene expression levels were based on cohort (N=93) 
specific median expression levels.  
The reliability of our radiomic pipeline was assessed by Intraclass Correlation 
Coefficient (ICC) values across institutions, scanner etc. before and after normalization 
steps for the features in the final predictive model. Additionally, the non-normalized 
features were tested for their ability to predict the outcome. 
 
Patient and mice multivariable predictive modeling 
Radiomic feature selection and classification model building was performed by 
implementing gradient boosting from the XGboost package (eXtreme Gradient Boosting) 
and works by implementing gradient boosting. The XGboost algorithm works by converting 
weak learners to strong learners using the boosting technique, in which trees are developed 
with the help of information from the previously grown trees and passing that information 
from one tree to another iteratively. Hence, slowly the trees to learn from the data and 
improve its prediction by minimizing the loss function or mis-classification error rate.  
XGboost enables parallel computation, regularization, cross validation, missing value 
imputation (if needed) and tree pruning [37]. 
For classification and model building, we used gbtree booster of XGboost and built 
binary logistic regression model to classify patients into high and low POSTN groups based 
on the selected radiomic features resulted from LASSO regularization. We performed 
hyperparameter tuning required for tree booster and cross validation using Leave One Out 
Cross Validation (LOOCV) over 100 iterations (n rounds = 100) to avoid overfitting and 
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acquire best prediction model that has better accuracy, AUC, sensitivity, specificity and p 
values. 
 Besides LOOCV, a 50% random split was used to train and test the model for 
outcome. ROC analysis and analysis with a 95% Confidence Interval (CI) were implemented 
to measure the model accuracy. AUC, sensitivity, specificity, PPV, NPV and p-values for 
each LOOCV and prediction output were calculated. 
 
Translational Causality Investigations 
Two independent GSC lines upon validation of efficient short hairpin RNA (shRNA) 
mediated POSTN knockdown were used to develop orthotopic tumors in mouse brains. See 
supplemental methods for details. In brief, leveraging a controlled preclinical experimental system 
for mechanistic validation of imaging genomics, we illustrate the potential for radiogenomic 
causality beyond mere correlation. First, we screened 47 GSC lines that met three criteria: high 
POSTN expression, expression of stemness markers, and their ability to produce stable orthotopic 
xenograft tumor using primary GSC lines to most faithfully replicate human GBM (Supplementary 
Fig. S1). First, we used gene expression microarray and quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) to select two GSC lines (GSC11 and GSC126) which met the 
latter criteria. We then transduced these GSC lines with lentiviruses containing a doxycycline-
inducible shRNA against POSTN, which co-expressed GFP via an IRES, thereby allowing 
visualization/isolation of knockdown cells both in-vitro and ex-vivo (Supplementary Fig. S2) and 
selected puromycin resistant stable clones with significant knockdown of POSTN at both the 
messenger RNA and protein levels (Supplementary Fig. S3). These clones were orthotopically 
implanted into nude mice (N=40). MRI was used to confirm the growth of the xenograft tumors 
(Fig. 3e). Ex-vivo flow-sorted cells from the control (APC+ve) and POSTN-knockdown 
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(APC+veGFP+ve) mouse tumors (Supplementary Fig. S2) were subjected to RNA extraction and 
qRT-PCR for POSTN. Those cells from knockdown tumors showed a significant decrease in POSTN 
mRNA levels (Fig. 3a); we also performed xenograft tumor immunohistochemistry to confirm that 
the POSTN-knockdown tumors had significantly lower POSTN protein expression than that of 
control tumors (Supplementary Fig. S3). 
 
RESULTS 
 
Robust high-throughput radiomic and radiogenomic pipeline 
We established a robust image analytical pipeline consisting of image segmentation, 
radiomic feature extraction, feature normalization and selection, and predictive model 
generation (Fig. 1). For an approach to be readily transferrable to the clinic, it must be 
robust; our analytical pipeline demonstrated high accuracy, precision, and reliability across 
patients, institutions, and different vendors of MRI scanners with different magnetic field 
strengths (Supplementary Tables 1a–b). Briefly, we obtained the outline and corresponding 
volume of the three GBM phenotypes (edema/invasion, enhancing active tumor and 
necrosis) by semi- automated consensus segmentation; consensus segmentation produces 
stable results compared to single- user segmentation [39] (Fig. 1a). The original MR images 
and corresponding segmented masks underwent image preprocessing for extraction of stable 
and comparable quantitative image features (Supplementary Figs. S4–S6). The inherent 
variability of MR signal intensities makes direct analysis of images obtained from different 
scanners/vendors difficult; thus, MR radiomic studies to date have mainly focused on data 
from single scanner and identical protocols [40, 41] and only a small number of studies have 
utilized data from multiple MR scanners/protocols [42, 43]. Thus, we employed a brain-
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tissue focused normalization consisting of two steps (i) skull stripping [25] and Nyul 
normalization (brain-specific normalization) [27], followed by a patient-specific 
contralateral hemisphere MRI normalization that allows for the extraction of stable 
quantitative radiomic features (Fig. 1b). Brain tissue images were first obtained by 
excluding extra-cerebral tissues such as skull, eyeballs, fat, and skin through skull stripping, 
and further used for normalization. Skull stripping is an important step in studies relying on 
intensity levels; however, to our knowledge, it has not been employed along with Nyul 
normalization before. The effectiveness of Nyul normalization compared to other image 
normalization techniques has been established [28]. In our study, we demonstrate its 
applicability in GBM. The combination of skull stripping, brain-tissue focused normalization 
and patient-specific normalization are unique to this study and provided comparable cross-
platform, cross-institution radiomic features as demonstrated qualitatively in TCGA pre– and 
post– patient-specific normalization plots, Supplementary Figs. S4–S6. This novel pipeline 
was employed for all imaging and statistical radiomic and radiogenomic analysis in our 
study. 
 
Qualitative and quantitative (volumetric) MRI is unable to classify GBM based on 
prototype POSTN gene expression level in patients and animal models 
 We evaluated POSTN expression levels in mesenchymal (MES) and proneural (PN) 
subgroups of GBM and found that expression of POSTN is highly correlated with MES 
subgroup (Fig. 2a). Gene set enrichment analysis (GSEA) of whole genome expression 
profiles of patient with high POSTN vs low POSTN expression (grouped according to median 
cutoff), revealed that high POSTN expression was significantly correlated with hallmarks 
such as epithelial mesenchymal transition (p-value<0.001, FDR q-value: 0), angiogenesis (p-
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value<0.001, FDR q-value: 0.001) etc. (Fig. 2b). As suggested by GSEA, patients with high 
endothelial proliferation, as extracted from Cancer digital slide archive [49] 
(http://cancer.digitalslidearchive.net/), (n=232) displayed significantly higher levels of 
POSTN expression (p-value: 0.0027) in comparison to that with low endothelial proliferation 
(N=152) (Fig. 2c and d). However, qualitative and quantitative volumetric analyses of MRI 
scans of patients with high and low POSTN expression appeared indistinguishable (Fig. 2e) 
and illustrated statistically insignificant variations, when various segmented volumes were 
quantified (Fig. 2f). 
 
While in animal models, when GSEA of whole genome expression profiles of ex-
vivo flow-sorted cells from the control (APC+ve) and POSTN-knockdown 
(APC+veGFP+ve) mouse tumors was performed, hallmarks such as angiogenesis (p-value: 
0.002, FDR q-value: 0.001) and epithelial mesenchymal transition (p-value<0.001, FDR q-
value: 0.041) etc. were enriched in control (i.e. high POSTN tumors) (Fig. 3b). Furthermore, 
as suggested by GSEA and confirmed by orthotopic xenograft tumor immunofluorescence, 
the control mice from both GSC11 and 126 cell lines, with high POSTN expression, 
displayed significantly higher levels of Ki67 and CD31+ve endothelial cells (p-values: 
<0.001) in contrast to tumors from the knockdown orthotopic mouse model (low POSTN) 
(Fig. 3c and d and Supplementary Fig. S7). Similar to GBM patients grouped according to 
POSTN expression levels, both GSC11 and 126 derived control and POSTN-knockdown 
tumors developed qualitatively similar growth and phenotype volumes and quantitative 
analyses revealed no significant difference in volumes of contrast enhancement or 
peritumoral edema/tumor invasion between the two groups of mice (Fig. 3e, f).  
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Radiomics predict genomic heterogeneity in GSC derived orthotopic tumors and GBM 
and is conserved across patient and mouse xenograft tumors 
We then sought to determine whether radiomics could correctly identify patients with 
differential expression of POSTN and the altered POSTN expression levels between control 
and knockdown tumors across the two transplanted GSC lines. Our analyses of radiomic 
features displayed similarities between high-POSTN GBM in mice and in humans, 
specifically, as seen in 64 gray-level and heterogeneity histograms (Fig. 4a). We then tested 
the radiomic feature predictive performance by LOOCV to distinguish tumors with high 
POSTN (control) and low POSTN (knockdown) expression levels in two GSC lines (Fig. 4b) 
(AUC 92.26%, sensitivity 92.86%, specificity 91.67%; p-value 2.68E-05). Our results 
showed that unlike conventional qualitative and quantitative volumetric assessments, 
radiomic analyses (17 radiomic features) correctly distinguished tumors with differential 
RNAi-mediated POSTN status lines. Furthermore, we used radiomic analysis for further 
characterization of the mouse and human tumors. Towards this, to determine the power of 
radiomic features to predict targeted gene expression levels in tumors across species (mouse-
to-patient), we first generated and validated a radiomic feature-based model that successfully 
identified tumors based on POSTN levels in four mice cohorts across two GSC lines. As 
shown in Fig. 4b, specific radiomic features in this model significantly distinguish control 
and knockdown xenograft tumors (AUC 92.26%, sensitivity 92.86%, specificity 91.67%; p-
value 2.68E-05). Accordingly, radiomic features obtained using GBM patient cohort reliably 
predicted POSTN status in this cohort (Supplementary Table 3; 48 radiomic features). Both 
cross-validation (AUC 99.17%, sensitivity 97.83%, specificity 97.87%; p-value <2e-16; 
Supplementary Fig. S8) and prediction (AUC 76.56%%, sensitivity 73.91%, specificity 
78.26 %, p-value 0.00026 Fig. 4c) in a non-overlapping validation set were highly 
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statistically significant. As a measure of reliability across institutions, we observed a 
consistent decrease in ICC value for these 48 features (ranging from -7% to -104%) after 
normalization. This decrease was significant as the non-normalized features failed to predict 
POSTN levels in the patient cohort (data not shown). Furthermore, analysis with radiomic 
features (48 radiomic features) selected for their ability to predict POSTN levels in mouse 
orthotopic tumors showed significant LOOCV of POSTN levels in the patient cohort (AUC 
93.36%, sensitivity 82.61%, specificity 95.74%; p-value 2.021E-15; Fig. 4d, 
Supplementary Table 2). Finally, radiogenomic POSTN prediction was performed in a 
prospective manner in individual patients; these radiogenomic maps showed gene expression 
status (Fig. 4e).  This is summarized for the patient in a radiogenomic clinical report card. 
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DISCUSSION 
In this study, for the first time to our knowledge, we demonstrate a causal linkage between 
imaging radiomics and genomics. We tested our hypothesis using targeted genetic interventions. 
Herein, we demonstrate that gene expression, specifically POSTN expression, drives a specific 
imaging feature phenotype. In addition, we demonstrate that tumors with specific genomic 
expression profiles harbor distinct radiomic profiles. Finally, we show that patients harboring 
tumors with a distinct gene expression profile share significantly concordant radiomic features 
with their matching preclinical murine xenograft counterparts.  
Fundamental to radiogenomic analysis is the presumption that expression of specific sets of 
genes or driver mutations impact extractable imaging features, but this presumption has not been 
directly demonstrated in a highly robust model. Our results suggest that imaging features, 
specifically radiomic features, are at least in part genetically-driven, and subtle genomic changes in 
tumor tissue are captured by radiomic changes on imaging. Additionally, our results show that 
POSTN may potentially be responsible for maintenance of a mesenchymal program and 
angiogenesis in GBM (a link recently illustrated in Park, S.Y. et al.) [20]. These findings support 
the hypothesis that the radiogenomic functional relationships can be quite robust and may contain 
significant causal linkages between MR imaging features and genetically-driven tumor phenotypes.  
Technically underpinning this, we developed and evaluated a novel radiomics pipeline for 
analysis of standard of care clinical MR images that is scalable and provides widespread 
applicability for high-throughput cross-vendor and software platform image processing and 
analysis of medical imaging applied to human solid tumors and preclinical tumor models. Multiple 
innovative steps were required for this to occur and developed throughout this process. We 
established and applied two unique steps of image normalization: first, brain-specific normalization; 
and second, patient-specific contralateral hemisphere MRI normalization; these allowed for robust 
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cross-platform (vendor), cross-institution patient cohort analysis and comparison. Genomic 
predictions were significant in the TCGA dataset, despite these data being collated from six 
different medical centers across the United States and patients having undergone imaging with MRI 
scanners from different vendors using different image acquisition protocols. This unique 
combination of normalization steps have not been previously used within the radiomics/tumor 
assessment field, although the effectiveness of Nyul normalization has been shown in image 
analysis of normal human MRIs and multiple sclerosis [28]. The integration of a patient-specific 
normalization process is new to the radiomics field and its application in conventional imaging at 
large has not been used in this setting. Thus, herein, we developed a novel radiomic pipeline that is 
agnostic to MRI scanner vendor, institution, and protocol.  
Further, we developed a pipeline that can robustly extract microscale information beyond the 
resolution of the naked human eye. As our data demonstrate, qualitative and quantitative 
(volumetric) MRI assessments did not detect any differences between POSTN knockdown and 
wild-type xenograft tumors (Fig. 3e-f); however, radiomic analysis showed distinct 
radiophenotypic differences between these two groups. (See pre– and post–patient-specific 
normalization plots, Supplementary Figs. S4–S6). This enhanced radiomics analysis method may 
unlock previously inaccessible data for clinicians and investigators independent of where, when and 
how images were acquired. The radiomic software developed herein is scalable, potentially 
enabling multi-institutional collaborations, big data collation and integration into clinical care, 
clinical trials, and research across various arenas. 
POSTN, expressed in glioma cells including glioma stem-like cells (GSCs) and secreted to 
extracellular matrix in tumor microenvironment, is involved in invasion as well as perivascular 
niche formation, metastasis and macrophage recruitment [45] [46]. More recent studies 
demonstrate POSTN’s role in promoting glioma invasion, tumor recurrence, and resistance to anti-
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angiogenic therapy [20, 47].  The peritumoral region in gliomas harbors a mixture of edema and 
invasive, aggressive tumor cell, a key determinant of tumor recurrence and poor patient survival 
[48]. Given POSTN’s role in glioma invasion as detailed above coupled with our previous imaging 
genomic findings, we utilized POSTN as our gene prototype. In our study, tumors with distinct 
POSTN expression levels harbored distinct imaging features that were not only associated with but 
also predictive of expression levels in both patients and murine models. Likewise, the preclinical 
model-derived radiomic features significantly predicted concordant gene expression in our patient 
GBM cohort (N=93). This is a uniquely novel finding and demonstrates that detection of selected 
genomic traits is conserved in appearance on imaging across species and can be expected to further 
facilitate integration of radiomics and radiogenomics into clinical and co-clinical trials. For a 
method to be translated into clinical practice robustness, generalizability and scalability of the 
technique are required [50]. Employing well-known robust statistical methods, we used non-
overlapping discovery and validation sets to meet and achieve high protocol standards [51]. Giving 
further credence to the generalizability and scalability of our radiomic model is the fact that the 
pipeline is applicable beyond solid tumors and to other types of imaging sequences such as 
functional MRI [52]; in a previously published study by our group, we found that radiomics can 
detect and discriminate between areas of true activation in regions of eloquent cortex versus artifact 
[52].       
The need to establish robust imaging-genomic correlations and the importance of radiomic 
tools to interrogate tissue is supported by multiple studies including the study by Kickingereder et 
al. who concluded that tumor volumes, perfusion, diffusion, and other MRI parameters are not 
sufficient for reliable and clinically meaningful predictions of molecular characteristics in patients 
[53]. A lack of established causality as to the molecular underpinnings of imaging has been a major 
impediment towards general clinical acceptance of radiogenomics. However, this study 
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demonstrates that radiomic assessment can predict genomically distinct tumors with high 
sensitivity, specificity, accuracy and evaluate pertinent genomic alterations towards providing 
detailed prediction maps of the molecular GBM landscape. This method will not replace but 
complement conventional genomic testing, such that noninvasive genomic profiling may enhance 
diagnosis, help stratify patients and determine early response to targeted therapy; imaging 
radiomics also assess the entire three-dimensional tumor structure and may enable monitoring of 
genomic traits at a specific time for patients in whom biopsy or surgery cannot be performed or 
when cost of care limits repeated genomic profiling. Hence, comprehensive radiomics can 
complement genomic information obtained via biopsy or tumor resection in cancer care. It can also 
be anticipated that longitudinal alterations in radiomic features can be used in combination with 
current response assessment criteria such as RANO, RECIST1.1, irRC, etc. for a more accurate 
and early assessment of treatment response. Radiomics provides significantly increased predictive 
power and higher biomarker accuracy based on inherent tumor imaging features and pixel-based 
heterogeneity.  
Despite this study being the pilot in establishing radiogenomic causality within the 
radiogenomic literature, prospective validation using spatially matched image-guided brain tumor 
biopsies in patients and animal models are needed to further validate the spatial distribution of the 
molecular underpinnings of imaging in brain cancer. Currently, topographical spatial encoding of 
the genomic landscape using image- guided biopsies is underway at our institution. Another 
limitation of the study, is that the spatial resolution (voxel size) of the human MRI is larger 
compared to the xenograft MRI; these differences could potentially affect the extracted radiomic 
features since the distance of 1-voxel used for the calculation of the GLCM matrix varies in size.  
Preprocessing steps that account for varying resolutions, such as up-sampling or down-sampling 
the volume to one resolution could be utilized, however, the goal of our study was to use the 
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images with the resolution dictated by their respective acquisition protocols, thus no pre-
processing steps were performed on xenograft models. Further, the results of our analyses (high 
accuracy, sensitivity and specificity) could indicate that additional preprocessing steps to account 
for resolution differences may not be necessary when evaluating the whole tumor compared to 
voxel-based radiomic analysis.  
In summary, we present a clinically-applicable and -meaningful analytical imaging method 
for performing high- throughput image analysis that can capture key genomic events in brain cancer 
patients. Our radiomic analysis pipeline is a biologically validated test method. Further, the 
generalizability and scalability to most types of medical imaging and solid tumors can be 
anticipated and preliminary results underway at our institution using our pipeline are promising. It 
also has use beyond clinical diagnosis and prognosis, as it allows for human-mouse matched co-
clinical trials, in-depth endpoint analysis, and upfront, noninvasive, high-resolution radiomics-
based diagnostic, prognostic, and predictive biomarker development. 
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FIGURE LEGENDS (Total # for Figures and Tables: 5) 
Figure 1: Radiome sequencing pipeline for solid tumor (glioblastoma) and tissue 
characterization. (a) Semi- automated segmentation of the three imaging phenotypes: 
necrosis (left), post–contrast active enhancing tumor (middle), and Fluid Attenuated Inversion 
Recovery (FLAIR) peritumoral edema/invasion, representing edematous tumor as well as 
sites of cellular invasion into brain tissue (right). (b) Automated segmentation-based radiomic 
feature extraction is followed by patient specific normalization and feature selection, which 
consists of   the normalization of contralateral normal-appearing white matter as an internal 
control normalizer to account for various potential intra- and inter- institutional biases, a 
crucial step that ensures comparability. The next step is volume-dependent feature generation, 
which uses the necrosis, post–contrast enhancement, and FLAIR volumes for the 
corresponding radiomic feature sets acquired from the respective sequences, thus doubling the 
amount of radiomic features and creating a set of tumor volume–independent and –dependent 
radiomic features. Finally, this homogenous dataset can then enter feature selection and 
predictive modeling for any GBM trait of interest. 
 
Figure 2: Qualitative and quantitative MRI parameters are unable to distinguish 
genomic and histologic heterogeneity in GBM patients. Association of POSTN with distinct 
genomic and histologic heterogeneity in GBM. (a) POSTN expression is significantly higher in 
mesenchymal sub-group of GBMs in comparison to proneural sub-group. Expression levels of 
POSTN in mesenchymal (n=124) and proneural (n=113) sub-group is shown as box plot (p-
value <0.0001). (b) Gene set enrichment analysis shows significant enrichment of key 
hallmark signatures in patients with high POSTN expression. Table shows top 10 enriched 
gene set in patients with high POSTN expression when compared to patients with low POSTN 
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expression. Their respective rank, net enrichment score (NES), p-values, and FDR q-values are 
shown. (c) POSTN expression is higher in tumors with endothelial proliferation versus the 
tumors with undetectable endothelial proliferation. (d) Expression levels of POSTN in tumors 
with endothelial proliferation (n=232) and with undetectable endothelial proliferation (n=152) 
is shown as box plot. *: p-value 0.0027. Qualitative and quantitative MRI parameters are 
unremarkable in patient with high or low POSTN expression. (e)Tumors from POSTN High 
and POSTN Low appear qualitatively (left panels) and quantitatively (right panels) 
indistinguishable on representative MRI scans. (f) The box plot shows quantification and 
comparison of volumes of necrosis, contrast enhancement and edema (T2) in POSTN High and 
POSTN Low groups of patients. p-values between groups were not significant. 
 
Figure 3: Qualitative and quantitative MRI parameters are unable to distinguish 
genomic and histologic heterogeneity in orthotopic GBM model system. (a) Ex vivo 
validation of knockdown of POSTN in GSC11 and GSC126. Quantitative real time PCR 
analysis for determination of expression levels of POSTN gene in knockdown (KD) and 
control tumor cells isolated from mouse brain ex vivo. Relative expression levels of POSTN 
after normalization to that of GAPDH in respective samples is presented (N=3). (b) Gene 
set enrichment analysis of whole genome expression profiles of tumor cells (ex vivo) from 
control and KD mice. Top 10 gene set enriched in control tumor cells are shown in the table. 
Their respective rank, net enrichment score (NES), p-values, and FDR q-values are shown. 
(c) Immunohistochemistry staining of xenograft tumor sections from control and KD mice 
using anti-CD31 antibody. Nuclei are counterstained with hematoxylin. Respective cell lines 
giving rise to orthotopic tumors are labelled on the side of micrographs. Scale bar is 100µm. 
(d) Quantification of CD31 positive cells in control and KD tumors are shown in the graph. 
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*: p-value <0.001. (e) Representative MRI scans and segmentations of GSC11 and GSC126 
xenograft tumors from control (N=5 and 7, respectively) and POSTN-knockdown (KD) 
(N=5 and 9, respectively) animals. Tumors from POSTN-wildtype (control) and POSTN-KD 
GSC11 and GSC126 mice appear qualitatively (top) and quantitatively (bottom) 
indistinguishable on T1WI and T2WI with a 7T MRI system. (f) The box plot shows 
quantification of volumes of contrast enhancement and edema (T2) in control and POSTN-
KD groups. p-values between groups were not significant. 
 
Figure 4: Radiomics based features are conserved and are predictive of POSTN levels 
across xenograft and human tumors. (a) High POSTN tumors from patients and orthotopic 
xenograft mice (Control) (left) show greater similarity of textural heterogeneity at 8 Gray and 
64 Gray levels and are distinct from that of low POSTN tumors from patients and orthotopic 
xenograft mice (KD) (right). (b) LOOCV ROC curve depict the performance of the GSC11 
and GSC126 mouse-based predictive model using 17 radiomic features to predict control and 
KD mice across cell lines with 92.26% accuracy and p-value 2.68E-05. 95% CI, sensitivity, 
specificity, PPV, NPV of models are shown within each plot. (c) ROC curve depicts the 
performance of TCGA training set (N=46) based predictive model using 48 radiomic features 
to predict POSTN expression levels in validation set (N=47) with 76.65% accuracy. (d) The 
LOOCV* ROC curve shows the association of 17 radiomic features derived from GSC11 
and GSC126 mice from panel (b) with 93 patients with endogenous high and low POSTN 
expression levels. (e) Radiome sequencing in clinics. Radiogenomic probability maps and 
radiome sequencing clinical report cards for two representative patients. Summary of the 
radiomics-based prediction of the genomic events/status of GBM for two representative 
patients. The left panels show the segmented patient brain MRIs delineating the tumor. The 
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right panels show the radiome sequencing clinical report cards summarizing the status of 
POSTN expression. A check mark indicates that the prediction was correct. 
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TABLES 
 
Table 1a: TCGA Patient Demographic Table.  
 
Patients with High POSTN level 
expression (n=39) 
Patients with Low POSTN 
level expression (n=40)  
Age (years) 60 ±24 63±18 
 
Sex (male/female) 28(71.7%)/11(28.2%) 23(57.5%)/17(42.5%) 
 
KPS (≥80/<80/Not reported) 25(64.1%)/4(10.2%)/ 9(23 29(72.5%)/6(15%)/5(12,5%)
 
 
Table 1b: Rembrandt Patient Demographic Table *. 
 
Patients with High POSTN 
level expression (n= 7) 
Patients with Low POSTN level 
expression (n= 7)  
Age (years) 59±12 51.5±5 
 
Sex (male/female/not reported) 3 (43%)/2(28.5%)/2 (28.5) 1 (14.25%)/1(14.25)/5(71.5%) 0.552 
KPS (≥80/not reported) 4(57%)/3(43%) 2(28.5%)/5 (71.5%) 0.473 
*demographic information was missing for 7 out of the 14 patients used from Rembrandt database.  
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